|
F.G. Ivanova, T.I. Nikolaeva, N.I. Spiridonova, L.N. Afanasyeva, P.V. Nikiforov, T.N. Zharnikova
Clinical experience with the use of combination drug therapy in the first line treatment of metastatic non-small cell lung cancer
|
№14 / 2023
|
|
O.O. Gordeeva, K.A. Ivanova, A.A. Meshcheryakov
Ceritinib in the treatment of ALK-positive non-small cell lung cancer
|
№11 / 2023
|
|
O.O. Gordeeva, N.A. Meshcheryakova, A.A. Meshcheryakov
Lorlatinib in the treatment of ALK-positive non-small cell lung cancer
|
№6-7 / 2023
|
|
A.I. Semenova (1), S.A. Protsenko (1), G.M. Teletaeva (1), D.Kh. Latipova (1), A.V. Novik (1, 2)
Neoadjuvant immunotherapy for non-small cell lung cancer
|
№11 / 2021
|
|
F.V. Moiseenko (1, 2)
Hope or error: can combinations of EGFR tyrosine kinase inhibitors and other drugs replace monotherapy?
|
№11 / 2021
|
|
E.V. Artemieva (1), F.V. Moiseenko (1, 2, 3), N.M. Volkov (1), V.V. Egorenkov (1), N.Kh. Abduloeva (1), A.A. Bogdanov (1), A.S. Zhabina (1, 2), N.V. Levchenko (1), V.M. Moiseenko (1)
Effectiveness of a shortened cycle of monoimmunotherapy in non-small cell lung cancer
|
№7 / 2021
|
|
F.V. Moiseenko, A.A. Kudryavtsev, A.V. Myslik, N.M. Volkov
NEW MOLECULAR SUBTYPES OF NON-SMALL CELL LUNG CANCER AND THE POSSIBILITIES OF THEIR TREATMENT
|
№17 / 2017
|
|
S.L. Gutorov, E.I. Borisova, M.E. Abramov, A.N. Lud, E.A. Arutyunyan
NON-SMALL LUNG CANCER. EXPANDING THERAPEUTIC OPPORTUNITIES: PEMBROLIZUMAB IN A NUMBER OF MALIGNANT TUMORS
|
№8 / 2017
|
|
D.D. Sakaeva (1), M.G. Gordiev (2)
BASIC MECHANISMS OF RESISTANCE TO EGFR TYROSINE KINASE EGFRINHIBITORS
|
№8 / 2017
|
|
Yu.A. Ragulin
NEOADYAVANT THERAPY OF NON-SMALL CELL LUNG CANCER: ARE THERE ANY PERSPECTIVES?
|
№8 / 2017
|
|
E.I. Borisova, S.L. Gutorov, M.E. Abramov
TREATMENT OF NON-SMALL CELL LUNG CANCER: THE NEXT STEP
|
№17 / 2016
|
|
K.K. Laktionov, E.V. Reutova, K.A. Sarantseva
ALK-POSITIVE NON-SMALL CELL LUNG CANCER AND ITS TREATMENT: A LITERATURE REVIEW
|
№18 / 2015
|
Русский
